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Inflammatory forms of arthritis such as rheumatoid ar-
thritis (RA) are chronic diseases that primarily affect pe-
ripheral synovial joints. The pathogenesis of RA is multi-
factorial, including genetic influences on susceptibility,
postnatal events in immune maturation, environmental fac-
tors, and amplifying cytokine networks that perpetuate in-
flammation (1). Many elegant models of transgenic and
gene disrupted mice provide insight into the pathogenic
mechanisms of these diseases. Some of these models such as
 
the K/BxN, TNF
 
 
 
 transgenic, IL-1 receptor antagonist
 
deficient, and human T lymphotropic virus type I (HTLV-I)
tax transgenic mice develop spontaneous disease. Other
models rely on the induction of disease by collagen inocu-
lation in DBA/J or humanized HLA transgenic mice, di-
rect intraarticular antigen or oligonucleotide administra-
tion, injection with bacterial cell walls, or by creating
immune complexes. The panoply of pathogenic mecha-
nisms illustrates the wide variety of initiating circumstances
that can ultimately lead to joint damage. In each case, the
final common pathway, i.e., synovial inflammation and
joint destruction, resembles RA. However, RA is a com-
plex, heterogeneous disease and the limitations of each ani-
mal model should be recognized.
Recently, one model has attracted particular interest, the
K/BxN model, wherein spontaneous arthritis occurs in
mice that express both the transgene encoded KRN T cell
 
receptor and the IAg
 
7
 
 MHC class II allele (2, 3). These
transgenic T cells have specificity for a self-peptide derived
from the glycolytic enzyme glucose-6-phosphate isomerase
(G6PI) and are able to breach tolerance in the B cell com-
partment resulting in the production of autoantibodies to
the same antigen (4, 5). Affinity-purified anti-G6PI Ig from
these mice can transfer joint specific inflammation to
healthy recipients (4). The mechanism for joint-specific
disease arising from autoimmunity to a ubiquitious autoan-
tigen has been puzzling. In a rapid succession of articles, in-
cluding one in this issue, some of the mechanisms of this
model are revealed. G6PI bound to the surface of cartilage
might be the target for immunoglobulin binding and sub-
sequent complement-mediated damage (6). Antibodies of
the IgG1 isotype are predominantly responsible for this dis-
ease, but monoclonal antibodies can only transfer disease in
pairs that bind to separate epitopes (7). In further experi-
ments, free Ig transferred paw swelling more efficiently
than fractions of preformed immune complexes (6). How-
ever, the dependence of the arthritis on Fc receptors and
the alternative complement pathway suggests that immune
complexes either form on the cartilage surface as an array
 
or in the circulation (8–10). Using various knockout mice,
some of the genes required for induction of joint inflamma-
tion and destruction induced by anti-G6PI antibodies have
been determined (Table I). In this model the inciting event
is the expression of an autoreactive T cell receptor in the
periphery; however, joint destruction is delegated by the
adaptive response to innate immune mechanisms and can
be transferred to animals that lack B and T cells (11).
Hence, it is the reverse of the usual immune paradigm:
adaptive immunity activates innate mechanisms rather than
the reverse.
Now that the mechanisms of this model have been ele-
gantly elaborated, it is important to ask how they relate to
the uniquely human disease known as rheumatoid arthritis.
Our scientific understanding of RA has evolved through
many stages, beginning with the discovery of anti-Ig au-
toantibodies called rheumatoid factors over 50 yr ago. This
led to the remarkable hypothesis in 1973 that RA repre-
sented an intraarticular immune complex disease mediated
by complement activation (12). This notion subsequently
fell into disfavor as antigen-specific T cell responses, both
autoimmune and otherwise, held primacy. In 1990, we
proposed that RA had a T cell–independent component
based on its cytokine profile (13), and this hypothesis was
recently updated and modified to incorporate the role of
innate immunity, partial transformation of synovial fibro-
blasts, and antigen-independent T cell mechanisms (14).
Although still controversial, this paradigm has been partially
validated by the relative success of anti-cytokine approaches
compared with anti-T cell therapy for RA.
The fortuitous discovery that K/BxN mice spontane-
ously develop arthritis after an initial T cell–dependent
phase with a subsequent T cell–independent phase fits very
well with this line of reasoning. As noted above, the patho-
genesis of the model has been precisely defined and is due
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to autoantibodies directed against a ubiquitous antigen that
seems to be adherent to cartilage surfaces. The next ques-
tion is “what does this have to do with rheumatoid arthri-
tis”? The answer is not at all clear at this point.
While few would argue with the participation of im-
mune complex–mediated inflammation in RA, it is quite
relevant to question whether it is specific for the disease
and whether it is a primary or a secondary phenomenon
(15). Anti-G6PI antibodies are not necessarily specific for
RA, and appear to be equally abundant in forms of arthritis
with an entirely different pathogenesis, clinical course, and
joint distribution like the spondyloarthropathies (16). The
localization of G6PI protein in the rheumatoid joint is con-
troversial, at times described in the synovial vasculature or
on the surface of cartilage (6, 17). However, only a limited
number of patients have been examined and we do not
know if a similar distribution occurs in other inflammatory
joint diseases. The lack of rheumatoid factors, a hallmark of
RA, is also a major difference with the murine model (2).
Although no animal models are actually RA, they can
help us understand normal inflammatory and immune re-
sponses or serve as vehicles to test therapeutic agents. It is
not yet known whether the K/BxN model is superior, or
even equivalent, to the ever-expanding universe of sponta-
neous and induced models (18, 19). As the basic mechanism
of the K/BxN model appears to be immune complex for-
mation on the surface of cartilage, it is very similar to col-
lagen-induced arthritis (CIA). Indeed, passive CIA induced
by a mixture of monoclonal antibodies that bind to the sur-
face of cartilage and fix complement is readily induced and
can, like the passive K/BxN model, be used to determine
which genes play a critical role in joint destruction or in-
flammation (7, 20). Like anti-G6PI antibodies, anti-type II
collagen antibodies can be detected in a subset of patients
but are not specific for RA (15, 17). After years of study,
most investigators believe that immune responses directed
against type II collagen are a potential contributory factor to
 
the disease but not a primary mechanism. It remains to be
seen if G6PI will merely join the growing list of autoanti-
gens implicated in RA (e.g., other collagen types, gp39,
proteoglycans, RA33, p205, and citrullinated proteins).
Perhaps the most interesting aspect of the K/BxN model
is not the end stage involving relatively nonspecific mecha-
nisms that may (or may not) be related to human disease;
instead, the intriguing breakdown of tolerance that permits
the formation of autoantibodies could be more relevant to
RA as well as other autoimmune conditions. Of particular
interest is how these adaptive immune responses, in turn,
activate innate immunity as an effector mechanism that can
inflame and damage target tissues. Careful dissection of this
pathway, including the influence of the genetic back-
ground, can define mechanisms of proximal events rather
than the undifferentiated final common pathway that is
clinically defined as arthritis. Exploration of these mecha-
nisms might provide important clues to etiology of self-
directed adaptive responses.
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